USPTO Grants Notice Of Allowance For Additional Patent On IceCure's Novel 'Cryogenic Pump' Technology, Reinforcing Co's Global IP Leadership in Cryoablation Technologies

• Further broadens the uses and applications of IceCure's cryoablation platform into a wide range of technology fields
• Over 50patents issued and allowed worldwide for IceCure's platform cryoablation technology

CAESAREA, Israel, Aug. 28, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for a continuation application based on the Company's issued patent titled "Cryogen Pump". The original patent, which was also issued by the European Patent Office and the Japan Patent Office, as well as the continuation, will be in effect until 2041.